Alert icon

To align with industry best practices for security and data integrity, Project Data Sphere is requiring users to upgrade their browsers to one that supports encryption protocol TLS 1.2 by December 15, 2017. On that date, Project Data Sphere will disable support of browsers that permit SSL 3.0/TLS 1.0. To prevent any disruption to your access to Project Data Sphere, you must take action.
This browser was not recognized and may not be compatible with TLS 1.2 or higher. Please check with the browser's developer to confirm.
To view information about this, please visit the FAQ. If you have any further questions, please contact us.

Back to the List
Type(s) of Cancer
CNS
Study Phase
Phase 3
Study Completion Date
November 2012
NCT00689221Uploaded 12-15-2020
Available for Download
PDS UID: Glioma_EMDSero_2008_441
Cilengitide for Subjects With Newly Diagnosed Glioblastoma and Methylated MGMT Gene Promoter - A Multicenter, Open-label, Controlled Phase III Study, Testing Cilengitide in Combination With Standard Treatment (Temozolomide With Concomitant Radiation Therapy, Followed by Temozolomide Maintenance Therapy) Versus Standard Treatment Alone (CENTRIC)
Files:
PROTOCOLCTP_EMD121974-011_final_redacted.pdf
CRFblankcrf.pdf
DATA DICTIONARYdatadict.xpt
DATA SUMMARYDescriptive_Stats_EMD121974_011.xlsx
DATA SUMMARYProc Contents Data Dictionary EMD121974_011.pdf
DATA (COMPARATOR ARM)DATA_XPT.zip
DATA (COMPARATOR ARM)DATA_SAS.zip